0
Cannabis Used to Be a Punchline. Now It’s in Alzheimer’s Clinical Trials.
For decades, cannabis was the punchline. Associated with the lazy stoner, framed as the gateway drug. The thing that disqualified you from being taken seriously.
In July 2026, researchers presented results from a placebo-controlled clinical trial at the Alzheimer’s Association International Conference in London. The trial gave a precisely formulated THC and CBD combination to 120 people with late-stage dementia.
The LiBBY Trial
The study was called LiBBY (Life’s end Benefits of cannaBidiol and tetrahYdrocannabinol). It was designed for a population that most clinical research ignores entirely: people with severe dementia who are hospice-eligible or receiving end-of-life care.
Agitation is one of the most distressing symptoms of late-stage dementia. Pacing, shouting, hitting, resisting care… It affects about half of all people with dementia near the end of life. Current treatments are limited to off-label use of antipsychotics, benzodiazepines and opioids, medications that carry serious risks and often don’t work.
Participants were randomly assigned to receive either a THC/CBD combination or a placebo. Nobody knew which they were getting. The formulation was 4mg THC and 200mg CBD, taken twice daily (8mg THC and 400mg CBD total per day).
By week two, the difference was already clear:
“These trial results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia.” – Co-lead investigator, Georgetown University School of Medicine
Why This Matters Beyond Dementia
And it didn’t test “cannabis”. It tested a specific formulation at a specific dose for a specific condition.
The lead investigator made this point directly: over-the-counter or commercially available THC and CBD products vary widely in composition, quality and dosing, making them potentially ineffective or even harmful. The results of this trial apply to a purified, supervised formulation, not a random gummy from a gas station.
The Dose Is the Science
The LiBBY trial didn’t work because it used just any cannabis. It worked because it used the right cannabinoids, at the right ratio, at the right dose, for the right condition.
That level of precision isn’t something you stumble into. It’s designed, tested, and measured.
Increase the THC without the CBD buffer, and the side effects change. Use a different delivery method, and the bioavailability changes. The compound alone is not the medicine, the formulation is.
That’s the principle that separates real cannabinoid science from the recreational noise.
That’s Our Principle at FK+
We're not claiming that FK+ treats dementia. That’s not what our products are for. But the principle behind the LiBBY trial is the same principle behind every FK+ product: specific cannabinoids, at specific amounts, formulated for a specific outcome. Because that’s the only way any of this works.
Every FK+ gummy is precisely dosed with cannabinoid ratios designed by plant scientists and herbalists. Every formulation includes functional botanicals at therapeutic levels. Everything is lab-tested, nothing is guesswork.
The LiBBY trial proved what good cannabinoid science looks like at the highest level. FK+ applies that same thinking to daily wellness: energy, focus, sleep, calm.
